Asset Details
Do you wish to reserve the book?
The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study
Do you wish to request the book?
The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study
2025
Overview
Objectives:
To investigate the effectiveness of Botulinum Toxin A (BTX-A) intravesical injections in improving quality of life (QoL) among pediatric patients.
Introduction:
Overactive bladder (OAB) in children impacts their QoL. Current treatments often have limitations, necessitating the exploration of alternative therapies.
Methods:
A quasi-experimental design was conducted in four Jordanian hospitals, with participants being parents of pediatric OAB patients aged 5 to 18 years. Statistical analysis was utilized for data analysis.
Results:
Results showed that BTX-A injections significantly improved QoL scores for pediatric OAB patients, with marked reductions in symptoms and enhanced well-being in the intervention group. Key demographic factors like household income and age at symptom onset were linked to QoL outcomes, and pre-treatment QoL varied by healthcare provider type.
Conclusion:
This study highlights BTX-A as a promising therapeutic and advocates for its broader adoption in pediatric urology to enhance the well-being and daily functioning of children with OAB.
Publisher
SAGE Publications,Sage Publications Ltd
Subject
